|
1
|
Ali AY, Farrand L, Kim JY, Byun S, Suh
J-Y, Lee HJ and Tsang BK: Molecular determinants of ovarian cancer
chemoresistance: New insights into an old conundrum. Ann N Y Acad
Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li F, Guo Y, Han L, Duan Y, Fang F, Niu S,
Ba Q, Zhu H, Kong F, Lin C, et al: In vitro and in vivo growth
inhibition of drug-resistant ovarian carcinoma cells using a
combination of cisplatin and a TRAIL-encoding retrovirus. Oncol
Lett. 4:1254–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Milella M, Falcone I, Conciatori F, Cesta
Incani U, Del Curatolo A, Inzerilli N, Nuzzo CMA, Vaccaro V, Vari
S, Cognetti F, et al: PTEN: Multiple functions in human malignant
tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bermúdez Brito M, Goulielmaki E and
Papakonstanti EA: Focus on PTEN regulation. Front Oncol. 5:1662015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou
H and Jia L: MicroRNA-130b targets PTEN to mediate drug resistance
and proliferation of breast cancer cells via the PI3K/Akt signaling
pathway. Sci Rep. 7:419422017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang H, Kong W, He L, Zhao J-J, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schöndorf T, Ebert MP, Hoffmann J, Becker
M, Moser N, Pur S, Göhring UJ and Weisshaar MP: Hypermethylation of
the PTEN gene in ovarian cancer cell lines. Cancer Lett.
207:215–220. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi X, Xiao L, Mao X, He J, Ding Y, Huang
J, Peng C and Xu Z: miR-205-5p mediated downregulation of PTEN
contributes to cisplatin resistance in C13K human ovarian cancer
cells. Front Genet. 9:5552018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amini-Farsani Z, Sangtarash MH, Shamsara M
and Teimori H: MiR-221/222 promote chemoresistance to cisplatin in
ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway.
Cytotechnology. 70:203–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gong J, Xing C, Wang LY, Xie SS and Xiong
WD: L-Tetrahydropalmatine enhances the sensitivity of human ovarian
cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade. J BUON.
24:701–708. 2019.PubMed/NCBI
|
|
13
|
Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu
FQ, Hu R and Wang MS: miR-106a promotes growth and metastasis of
non-small cell lung cancer by targeting PTEN. Int J Clin Exp
Pathol. 8:38272015.PubMed/NCBI
|
|
14
|
Fang Y, Shen H, Li H, Cao Y, Qin R, Long
L, Zhu X, Xie C and Xu W: miR-106a confers cisplatin resistance by
regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim
Biophys Sin (Shanghai). 45:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dhar S, Kumar A, Rimando AM, Zhang X and
Levenson AS: Resveratrol and pterostilbene epigenetically restore
PTEN expression by targeting oncomiRs of the miR-17 family in
prostate cancer. Oncotarget. 6:27214–27226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu B, Cai H, Zheng R, Yang S, Zhou Z and
Tu J: Long non-coding RNA 657 suppresses hepatocellular carcinoma
cell growth by acting as a molecular sponge of miR-106a-5p to
regulate PTEN expression. Int J Biochem Cell Biol. 92:34–42. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Zhang F, Sheng XG, Zhang SQ, Chen
YT and Liu BW: MicroRNA-106a regulates phosphatase and tensin
homologue expression and promotes the proliferation and invasion of
ovarian cancer cells. Oncol Rep. 36:2135–2141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheetham S, Gruhl F, Mattick J and Dinger
M: Long noncoding RNAs and the genetics of cancer. Br J Cancer.
108:2419–2425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou M, Wang X, Shi H, Cheng L, Wang Z,
Zhao H, Yang L and Sun J: Characterization of long non-coding
RNA-associated ceRNA network to reveal potential prognostic lncRNA
biomarkers in human ovarian cancer. Oncotarget. 7:12598–12611.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ren C, Li X, Wang T, Wang G, Zhao C, Liang
T, Zhu Y, Li M, Yang C, Zhao Y, et al: Functions and mechanisms of
long noncoding RNAs in ovarian cancer. Int J Gynecol Cancer.
25:566–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanchez-Mejias A and Tay Y: Competing
endogenous RNA networks: Tying the essential knots for cancer
biology and therapeutics. J Hematol Oncol. 8:302015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi
Y and Guo J: Long noncoding RNA associated-competing endogenous
RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen
Y, Ouyang J, Zhang L, Tan H, Chen R, et al: A long noncoding RNA
critically regulates Bcr-Abl-mediated cellular transformation by
acting as a competitive endogenous RNA. Oncogene. 34:1768–1779.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Davis S and Meltzer PS: GEOquery: A bridge
between the Gene Expression Omnibus (GEO) and BioConductor.
Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e47. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Revelle WR (Photographer), . psych:
Procedures for Personality and Psychological Research 2017.
|
|
33
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao J, Wu N, Liu X, Xia Y, Chen Y, Li S
and Deng Z: MicroRNA-142-3p inhibits cell proliferation and
chemoresistance in ovarian cancer via targeting sirtuin 1. Exp Ther
Med. 15:5205–5214. 2018.PubMed/NCBI
|
|
35
|
Zhang C, Wang M, Shi C, Shi F and Pei C:
Long non-coding RNA Linc00312 modulates the sensitivity of ovarian
cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Biosci Trends. 12:309–316. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mansoori B, Mohammadi A, Davudian S,
Shirjang S and Baradaran B: The different mechanisms of cancer drug
resistance: A brief review. Adv Pharm Bull. 7:339–348. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Juric D, Castel P, Griffith M, Griffith
OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, et
al: Convergent loss of PTEN leads to clinical resistance to a
PI(3)Kα inhibitor. Nature. 518:240–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo B, Kang N, Chen Y, Liu L and Zhang Y:
Oncogene miR-106a promotes proliferation and metastasis of prostate
cancer cells by directly targeting PTEN in vivo and in vitro.
Minerva Med. 109:24–30. 2018.PubMed/NCBI
|
|
40
|
Kang Y, Zhu X, Xu Y, Tang Q, Huang Z, Zhao
Z, Lu J, Song G, Xu H, Deng C, et al: Energy stress-induced lncRNA
HAND2-AS1 represses HIF1α-mediated energy metabolism and inhibits
osteosarcoma progression. Am J Cancer Res. 8:5262018.PubMed/NCBI
|
|
41
|
Zhou J, Lin J, Zhang H, Zhu F and Xie R:
LncRNA HAND2-AS1 sponging miR-1275 suppresses colorectal cancer
progression by upregulating KLF14. Biochem Biophys Res Commun.
503:1848–1853. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang X, Wang CC, Lee WY, Trovik J, Chung
TK and Kwong J: Long non-coding RNA HAND2-AS1 inhibits invasion and
metastasis in endometrioid endometrial carcinoma through
inactivating neuromedin U. Cancer Lett. 413:23–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miao F, Chen J, Shi M, Song Y, Chen Z and
Pang L: LncRNA HAND2-AS1 inhibits non-small cell lung cancer
migration, invasion and maintains cell stemness through the
interactions with TGF-β1. Biosci Rep. Jan 11–2019.(Epub ahead of
print). doi: 10.1042/BSR20181525. View Article : Google Scholar
|
|
44
|
Yang J, Shi M and Zeng Y: LncRNA HAND2-AS1
inhibits proliferation and promotes apoptosis of chronic myeloid
leukemia cells by sponging with micRNA-1275. Eur Rev Med Pharmacol
Sci. 23:2103–2111. 2019.PubMed/NCBI
|
|
45
|
Yan Y, Li S, Wang S, Rubegni P, Tognetti
L, Zhang J and Yan L: Long noncoding RNA HAND2-AS1 inhibits cancer
cell proliferation, migration, and invasion in esophagus squamous
cell carcinoma by regulating microRNA-21. J Cell Biochem.
120:9564–9571. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abdollahzadeh R, Daraei A, Mansoori Y,
Sepahvand M, Amoli MM and Tavakkoly-Bazzaz J: Competing endogenous
RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A
new look at hallmarks of breast cancer. J Cell Physiol.
234:10080–10100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Guo LL, Song CH, Wang P, Dai LP, Zhang JY
and Wang KJ: Competing endogenous RNA networks and gastric cancer.
World J Gastroenterol. 21:11680–11687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li H, Xu H, Shen H and Li H: microRNA 106a
modulates cisplatin sensitivity by targeting PDCD4 in human ovarian
cancer cells. Oncol Lett. 7:183–188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huh JH, Kim TH, Kim K, Song JA, Jung YJ,
Jeong JY, Lee MJ, Kim YK, Lee DH and An HJ: Dysregulation of
miR-106a and miR-591 confers paclitaxel resistance to ovarian
cancer. Br J Cancer. 109:452–461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Subramanian S: Competing endogenous RNAs
(ceRNAs): New entrants to the intricacies of gene regulation. Front
Genet. 5:82014.PubMed/NCBI
|
|
52
|
Ballantyne M, McDonald R and Baker A:
lncRNA/MicroRNA interactions in the vasculature. Clin Pharmacol
Ther. 99:494–501. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rao Y, Shi H, Ji M and Chen C: MiR-106a
targets Mcl-1 to suppress cisplatin resistance of ovarian cancer
A2780 cells. J Huazhong Univ Sci Technolog Med Sci. 33:567–572.
2013. View Article : Google Scholar : PubMed/NCBI
|
